Bionoxx Inc.

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Bionoxx is a R&D biotech company focuses on the clinical development of innovative immune-oncology treatments for cancer. Our platform technology (OTS-400) is based on oncolytic vaccinia virus armed with transgene that provides safety margin when added with myeloid modulation technology. Our lead product mOTS-412 is "Myeloid Modulating Oncolytic Vaccinia Virus" designed to demonstrate full potential of oncolytic vaccinia virus by regulating patient's systemic and local immune response favorable to oncolytic virus therapy.
OTS-400 also encodes unique target(UTTA) for CAR-T therapy particularly designed to express antigen highly selectively and effectively on solid tumor cell surface to overcome a major barrier of CAR-T therapy.
Our lead product completed manufacturing in Oct in 2019. We have recently submitted IND and is now under reviewed by Korean FDA. Our goal is to begin phase I study early 2020.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
IND under review by Korean FDA
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
IP & BD Manager
Bionoxx